ArticleJournal of ovarian research2025
Unveiling mitochondrial and PANoptosis-related biomarkers for premature ovarian insufficiency.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Pyroptosis in Patients with Ovarian Dysfunction and Infertility: Molecular Mechanisms and Therapeutics.Reproductive sciences (Thousand Oaks, Calif.) · 2026Review
- Lysine-specific demethylase 3A (KDM3A) protects against ovarian dysfunction in premature ovarian insufficiency by transcriptional activation of ATP-binding cassette sub-family A member 7 (ABCA7)-mediated mitochondrial homeostasis.Molecular biomedicine · 2026Article
- Mechanisms of mitochondrial dysfunction in premature ovarian insufficiency.Journal of ovarian research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdvances in diagnosis and treatment of premature ovarian insufficiency (POI) are urgently needed. Mitochondrial dysfunction and PANoptosis are associated with ovarian damage. In this study, we aimed to identify mitochondrial and PANoptosis-related biomarkers for POI.
methodsIntegrative bioinformatics analysis was performed based on RNA sequencing datasets from the Gene Expression Omnibus (GEO) database, combined with the MitoCarta3.0 database and PANoptosis-related genes. The feature differentially expressed genes (DEGs) were screened using machine learning methods. Based on the expression levels of mitochondrial characteristic genes (ACSM3, ALDH1L1, MAOB, OSBPL1A) and pan-apoptotic genes (NOS2, UCHL1) screened out by the above machine learning, the mitochondrial and PANoptosis phenotypic scores were calculated through the GSVA algorithm. Differential expression of biomarkers was validated in clinical samples, and the role of nitric oxide synthase 2 (NOS2) was explored in POI mouse models.
resultsFour mitochondrial-related genes (ACSM3, ALDH1L1, MAOB, and OSBPL1A) and two PANoptosis-related genes (NOS2 and UCHL1) were screened. The mitochondrial phenotype scores of the samples were positively correlated with PANoptosis scores. All biomarkers were downregulated in human granulosa cells. Notably, NOS2, identified as the most significant biomarker, was downregulated in the POI model. Moreover, the overexpression of NOS2 markedly suppressed cell death and reactive oxygen species (ROS) production in the ovarian tissues of POI mice.
conclusionsThe identified biomarkers may play key roles in the pathology of POI and serve as candidate biomarkers for its diagnosis and treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.